Intravitreal bevacizumab: a viable treatment for bilateral central retinal vein occlusion with serous macular detachment secondary to Waldenström macroglobulinaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|170|3|431-434

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.170, Iss.3, 2015-08, pp. : 431-434

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The 1 year outcome of intravitreal dexamethasone implant for macular edema secondary to central retinal vein occlusion

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapy of macular oedema: meta‐analysis

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 42, Iss. 7, 2014-09 ,pp. : 637-649

John Wiley & Sons Inc

Access to resources Recommend Favorite

Injections in retinal vein occlusions

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 42, Iss. 7, 2014-09 ,pp. : 650-655

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison – response

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 43, Iss. 5, 2015-07 ,pp. : 497-498

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion‐related macular oedema: a prospective randomized comparison – comment

By  

CLINICAL & EXPERIMENTAL OPHTHALMOLOGY, Vol. 43, Iss. 5, 2015-07 ,pp. : 497-497

John Wiley & Sons Inc

Access to resources Recommend Favorite